Cell Surface Markers Market is Expected to Exhibit a Strong CAGR during forecast period upto 2023

 

Market Highlights

The global cell surface markers industry is anticipated to hold a market value of USD 498 million in the year 2017 and is expected to grow at a CAGR of 8.4% during the forecast period. Cell surface markers or cell surface antigen work as monograms for identification and classification of cells. The proteins that are expressed on the cell surfaces often conveniently work as markers for specific types of cells.

Increasing expenditure in the advancement of healthcare technology, advancement in technology, acquisitions by companies and outlook for reduction of costs associated with disease diagnosis are expected to drive the growth in the market over the forecast period. For instance, in April 2014, Beckman Coulter, acquired Xitogen Technologies, a cytometer manufacturer. This acquisition helped Beckman Coulter to broaden its product offerings and enabled business expansion in Asia.  However, complex products and expensive instruments & reagents can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7410 

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the significant amount of research and development activities and well-developed healthcare infrastructure. According to the Organization for Economic Co-operation and Development(OECD), In 2016 united states has spent USD 464,324 million on research and development activities which is 2.7% of total GDP.  Europe is expected to hold the second largest position in the global market owing to the well-developed healthcare infrastructure. Asia-Pacific is expected to be the fastest growing market owing to the growing demand for user friendly targeted therapies. Moreover, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation

The global cell surface markers market has been segmented into product, source, cell type and application.

The market, on the basis of product, has been segmented into antibody and PCR array.

The global market, on the basis of source, has been segmented into mice, rat and others.

The global market, on the basis of cell type, has been segmented into T cells, B cells and NK cells. T cells are expected to hold the largest market share owing to high usage of them in research and diagnostics. NK cells are expected to grow at the fastest CAGR owing to increasing application of these types of cell.

The global cell surface markers market, by application, has been segmented into research, clinical and others. Research segment has been further divided into stem cell and immunology. Clinical segment is further divided into oncology and hematology.

Key Players

Some of the prominent players in the global cell surface markers market are Bio-Rad Laboratories, Inc., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc. , F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION, Thermo Fisher Scientific, BD, Abcam plc., QIAGEN, Danaher, GenScript, Merk KGaA, BioLegend, Inc., Cell Signaling Technology, Inc., Bio-Techne and Others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/cell-surface-markers-market-7410 

Veterinary Laboratory Testing Market to Witness Widespread Expansion During 2020 to 2023

 

Market Highlights

The global veterinary laboratory testing market is expected to grow at a CAGR of 10.1% during the forecast period.

Increasing expenditure on pet insurance, growth in the number of veterinary practitioners, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.

However, high cost of veterinary testing and complications associated with the tests can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7326 

Regional Analysis

Geographically, the Americas is anticipated to dominate the global veterinary laboratory testing market owing to the increasing cases of animal disease and technological advancements in veterinary diagnostics. For instance, in 2016, IDEXX Laboratories, Inc. launched the Rapid Visual Pregnancy Test for cattle. With the new test, veterinarians can more quickly identify open cows using whole blood samples collected before the farm visit. Europe is expected to hold the second largest position in the global veterinary laboratory testing market. The market growth in this region is attributed to the rising expenditure on pet insurance. The Veterinary Laboratory Testing Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the awareness regarding use of sterile consumables for lab testing and rising healthcare spending. The Middle East & Africa contributes least in the global market for veterinary laboratory testing.

Key Players

Some of the global veterinary laboratory testing market companies are Abaxis, Inc., BIOCHECK Inc., Biomérieux SA, Henry Schein, Inc., Heska Corporation, Idexx Laboratories, Idvet, Neogen Corporation, Pfizer, Qiagen N.V., Randox Laboratories, Ltd., Thermo Fisher Scientific, VCA Inc., Virbac, Zoetis, Inc. and others.

Segmentation

The global veterinary laboratory testing market has been segmented into animal type, technology, product, and end user.

The market, on the basis of animal type, has been segmented into companion animal and livestock animal. The companion animal segment is further classified as dogs, cats, horses and others. The livestock animal segment is further classified as cattle, pigs, poultry and others.

The market, by technology, has been segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others.

The clinical biochemistry segment is further classified as clinical chemistry analysis, glucose monitoring, and blood gas & electrolyte analysis. The clinical chemistry analysis segment includes clinical chemistry reagent clips and cartridges and clinical chemistry analyzers. The glucose monitoring segment includes blood glucose strips, glucose monitors and urine glucose strips. The blood gas & electrolyte analysis segment includes blood gas and electrolyte reagent clips and cartridges and blood gas & electrolyte analyzers.

The immunodiagnostics segment is further classified as ELISA tests, lateral flow assays, allergen-specific immunodiagnostic tests, immunoassay analyzers, and others. The lateral flow assays segment includes lateral flow rapid tests, and lateral flow strip readers.

The hematology segment is further classified as hematology cartridges, and hematology analyzers.

The molecular diagnostics segment is further classified as polymerase chain reaction (PCR) tests, microarrays, and others.

The urinalysis segment is further classified as urinalysis clips & cartridges/panels, urine analyzers, and urine test strips.

The market, by product, has been segmented into consumables and instruments.

The market, by end user, has been segmented into veterinary hospitals & clinics, in-house testing, research institutes, diagnostic laboratories, and others. The veterinary hospitals & clinics segment held the largest segment of the market in 2017. This can be attributed to the increasing incidence of zoonotic diseases. On the other hand, the academic institutes segment is estimated to be the fastest growing segment.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/veterinary-laboratory-testing-market-7326 

Single-Photon Emission Computed Tomography Market | Worldwide Top key Players Profile Analysis | Forecast till 2023

 

Market Highlights

The growing acceptance of Single-Photon Emission Computed Tomography (SPECT) accustomed by its technical advances is one of the major trends witnessed in the global SPECT market over the forecast period. Imaging devices are becoming more advanced, efficient, and evolved in terms of technology. The SPECT scanner has two integral parts namely computed tomography (CT) and a radioactive material (tracer). Basically, these tracers are used to diagnose and predict outcomes in various disease states by monitoring the therapeutic effects.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1339 

The SPECT market is expected to witness tremendous growth owing to the new 99mtc labelled agents for visualizing biologically significant events, and integration of X-ray tomography (CT) In SPECT. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for skilled professionals, and reimbursement issues, is likely to curb the market growth during the forecast period.

Segmentation

The global Single-Photon Emission Computed Tomography (SPECT) market is segmented into type, application, end-users. The Single-Photon Emission Computed Tomography (SPECT) market, by type, the market is segmented into hybrid SPECT systems, and standalone SPECT systems. On the basis of application, the Single-Photon Emission Computed Tomography (SPECT) market is bifurcated into oncology, cardiology, neurology, and others. On the basis of end-user, the market is segmented into hospitals, diagnostic imaging centers, academic & research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians for radioisotopes. Further, SPECT has reportedly been combined with CT and MRI to provide detailed anatomical and metabolic information. It is currently exhibiting a highly lucrative growth rate due to an increased use of SPECT for diagnosis of cardiac diseases, brain diseases, etc.

The European region is the second largest SPECT market over the forecast period due to high acceptance of SPECT in research & development along with the rising incidence of chronic disease like cancers are also accountable for the growth of the Single-Photon Emission Computed Tomography (SPECT) market. 

The Asia Pacific region is likely to develop at the uppermost CAGR for the Single-Photon Emission Computed Tomography (SPECT) market in the years to come. Moreover, the rising diagnostic care services both at the hospitals and at community level are expected to influence the market in a positive way. The Middle East and Africa accounts for the least market share due to low per capita income and lack of availability of well-trained healthcare professionals.

Key Players

Some of the key players in the global Single-Photon Emission Computed Tomography (SPECT) market are GE Healthcare, Siemens Healthcare, Koninklijke Philips N.V., Bruker Corporation, Mediso Ltd., Digirad Corporation, Spectrum Dynamics Medical, DDD-Diagnostic A/S, MiE America, Inc., CardiArc, Beijing Hamamatsu Photon Techniques INC., SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.

PNPMedM, NuCare Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/single-photon-emission-computed-tomography-market-7231

Global Biologics Market Expected to Grow with a healthy CAGR

 Market Highlights

Global biologics market growth is expected to drive at a CAGR of 8.6% during forecasted period 2017-2023 and reach till $425 million by end of 2023. Biologics are the drugs prepare or obtain from the biological organism. They are composed of protein, sugars or nucleic acids.  This drugs are basically used in treatment of cancer and diabetes. Increasing prevalence of these diseases across the globe is the major responsible factor for the growth of the market. Beside this increasing demand for the better treatment, rising regulatory convergence and better access to healthcare for all nations has provided fuel for the growth of the market. On the other hand, biologic drugs are highly complex in nature and they must be controlled under maintained condition. This type of atmosphere and quality control is very difficult and requires a huge capital. This may hamper the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1339 

On regional basis, global biologic market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. Almost 9% of total North America population is suffering from diabetes.  North America shares nearly half of the global biologic market due to increasing diabetic and cancer population, increasing healthcare expenditure and governmental support for the research and development. North America is followed by Europe. UK and Germany are the major contributor for the biologic market. Asia Pacific is the fastest growing region for the biologic market due to rapid development of health care sector and presence of rapidly growing economies like India and China. While Middle East and Africa has the least biologic market.

Segmentation:

Global biologic market is segmented on the basis of type into vaccines, blood products, proteins, gene therapy, and other. On the basis of application they are segmented into anemia, cancer, diabetes, and other. On the basis of source they are segmented as human, animal, microorganism, and other.

Some of the major players in the global neuromodulation market include Unilife Corporation (US), Sanofi (France), Retractable Technologies Inc. (US), Smiths Medicals (UK), Becton, Dickinson & Company (Germany), Terumo Corporation (Japan), Pfizer Inc. (US), Roche Diagnostics (Switzerland), Amgen (US), GSK Biologicals (UK), Lundbeck (Denmark), Novartis AG (Switzerland), AstraZeneca (UK), Bayer AG (Germany), Genzyme (US), Merck KGaA (Germany), Samsung Biologics (South Korea), Celltrion (South Korea), Addgene (US), Johnson & Johnson Inc. (US), Eli Lilly & Company (US), Bristol-Myers Squibb (US), Biogen Inc. (US).

Many of the major companies are focusing on introduction of new biologic drugs and advancement in the treatment of the diseases by minimizing the side effects of the drugs.

Unilife Corporation is a U.S. based developer, manufacturer and supplier of injectable drug delivery services. Precision-Therapy, Flex-Therapy, Imperium are the widely used injectors of this company.

Sanofi is a French multinational pharmaceutical company headquartered in France. This company has performing phase 3 trials on efpeglenatide and sotagliflozin for the treatment of diabetes and isatuximab for the treatment of Multiple Myeloma in 2017. ActHIB, DAPTACEL, Fluzone High-Dose and Imovax Rabies are some of the vaccines manufactured by this company.

Becton, Dickinson & Company a Germany headquartered company has introduced BD Neopak a prefillable glass syringe designed for high-volume injection of biologics.

Smiths Medicals an UK headquartered company is one of the leading pharmaceutical manufacturing and research company. Varivax SDV, Menactra VL, Adacel SYR and Decavac SYRG are some of the major vaccines of this company.

Eli Lilly & Company is a U.S. based pharmaceutical company. This company has recently got an approval for Olumiant for the treatment of Arthritics.

AstraZeneca an UK headquartered company has announced positive top-line results for its licensed asthma biologic benralizumab. Arimidex (anastrozole) and Casodex (bicalutamide) are some of the major drug by the company for the treatment of Cancer.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biologics-market-1339 

Microcarriers Market is Expected to Exhibit a Strong CAGR during forecast period upto 2023

 

Market Highlights:

The Global Microcarrier Market Growth is anticipated to hold a market value of USD 1.18 billion with an estimated CAGR of 5.9% during the forecast period. A microcarrier is a support matrix allowing the growth of adherent cells. The microcarrier system provides high cell yields without having to resort to bulky equipment and tedious methodology. The rise in the use of microcarrier technology for various cell-based applications, coupled with the advantages of the microcarrier system such as its support for high yield of cells, facilitation of polarization and differentiation of cells, and lower risk of contamination are expected to drive the growth of the market during the forecast period. Moreover, the rapid growth of the biologics industry also fuels the growth of this market. On the other hand, strict regulatory framework, and limitation in production of high-density cell culture may hinder the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6911 

The global microcarrier market is currently dominated by many market players. These players are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in March 2018, Danaher announced that it has entered into a definitive agreement to acquire Integrated DNA Technologies, a privately-held provider of high-value consumables for genomics applications in next generation sequencing, synthetic biology, molecular biology, gene editing and molecular diagnostics.

Regional Analysis:

The market in the Americas is expected to dominate the global Microcarrier market during the forecast period owing to the increasing incidence of cancer and other chronic diseases, a well-developed healthcare sector and growing number of venture capital investments. According to data published by Centers for Disease Control and Prevention (CDC), 1,633,390 new cases of cancer were reported in the year 2015, and 595,919 people died of cancer in the United States in the same year. The European market is expected to be the second-largest due to government funding and support of the healthcare sector coupled with the strategic expansion of biopharmaceutical companies in this region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income and rising demand for cell-based vaccines. The market in the Middle East and Africa is likely to account for the smallest share of the global microcarrier market. The market growth in this region can be attributed to the growing government initiatives.

Segmentation:

The global microcarriers market has been segmented into product type, application, and end-user.The market, on the basis of type, has been segmented into equipment, and consumables.The market, based on equipment, has been segmented into bioreactors, culture vessels, cell counters, filtration systems, and other equipment.The market, based on consumables, has been sub-segmented into media, reagents, and microcarrier beads.The market, based on media, has been further segmented into serum-based media, serum-free media, and other media.

The market, based on microcarrier beads, has been sub-segmented into cationic microcarriers, collagen-coated microcarriers, protein-coated microcarriers, and other microcarrier beads.The market, on the basis of application, has been further segmented into vaccine manufacturing, cell therapy, biologics manufacturing, and other applications.The market, on the basis of end-user, has been further segmented into pharmaceutical and biotechnology companies, research institutes, and contract research organizations.

Key Players

Some of the key players in the global microcarrier market are Thermo Fisher Scientific Inc., Lonza, GENERAL ELECTRIC COMPANY, Corning Incorporated, Sartorius AG, Danaher, Merck KGaA, Becton, Dickinson and Company, Eppendorf AG and HiMedia Laboratories.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/microcarriers-market-6911

Forensic Swab Market is Expected to Exhibit a Strong CAGR during forecast period upto 2023

 

Forensic Swab Market Overview:

The use of forensic swabs is gaining traction with the broadening of its applications. Swabs have been in usage for common applications, but their usage in forensic applications is one of the key reasons that is boosting the demand for the market. As per a report published by MRFR on the global forensic swab market, the market is expected to achieve a CAGR of 5.8% while accumulating revenues worth USD 49.09 Mn in the period of the forecast from 2018 to 2023. The market is expected to witness notable development due to the presence of notable players who are modifying the competitive landscape favorably.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6929 

The development of the forensic swab market is centered on the demand that is being generated from the forensic and medical sector primarily. The rise in crime rates worldwide entails an increased level of usage of swabs to conduct examinations to increase the accuracy of profiling. Moreover, the use of swabs to carry out medical tests for various conditions is increasing the development of the forensic swabs market. The use of genetic material in a criminal investigation to deal with questions pertaining to legal situations, such as criminal and civil cases is also increasing the demand for forensic swabs globally. Furthermore, the intensifying usage of forensic biotechnology in the administration of justice is raising the development pace of the market.

Additionally, the escalated level of spending from the government is anticipated to bolster the evolution of the market. Also, the expansion of the market into the untapped regional markets is forecasted to boost the level of development that can be achieved from the market. The market is projected to be restrained by the high costs DNA free forensic swabs and the relatively irregular supply of new products in the market.

Segmental Analysis

The analysis of the forensic swab market is segmentation on the basis of type of swab shaft, type, end-user, and region. On the basis of type, the forensic swab market is segmented into foam, flocked, and cotton tips. The foam type segment was found to be heading the market segment in 2017. The cotton swabs segment is projected to witness the highest CAGR through the forecast period. The segmentation on the basis of types of swab shaft segments the forensic swab market into wood stick shaft, polystyrene shaft, and others. The polystyrene shaft was found to be the topmost market portion in 2017 and is expected to observe the highest CAGR in the duration of the forecast period. The end user based segmentation of the market comprises of hospitals, forensic science laboratories, among others. The forensic science laboratories segment was in charge of the market in 2017 and is projected to carry on with its control in the forecast period.

Detailed Regional Analysis 

The regions of Europe, the Americas, Asia Pacific, and the Middle East and Africa are included in the regional analysis of the forensic swab market. The Americas region is responsible for the major market share in 2017 and is projected to control the forensic swab market. The Americas region is accredited for the principal regional market share due to factors such as the mounting number of forensic labs in the region, increasing number of criminal cases, and increased dependence on blood sampling. The rise in the number of forensic labs in the regions has also contributed to a growth in the number of microbiological tests. The development of laboratories in hospitals is also anticipated to support the forensic swab market in this region.

The European region is accountable for the ensuing principal market share in 2017. The expansion of the region is attributed to the increasing number of research labs and hospitals, and the escalation in accident cases is expected to boost the demand for swabs through the forecast period. The Asia Pacific region is estimated to exhibit a CAGR of 6.1% through the forecast period owing to the rising frequency of various diseases, demand for blood sampling, and an increasing number of forensic labs being set up in the region. On the other hand, the Middle Eastern and African region are estimated to see decelerated growth due to the restricted exposure to forensic labs and the low awareness levels in this region.

Competitive Analysis

The global forensic swab market’s growth is expected to be highlighted by the intense competition, frequent changes in government as well as rapid advances in the product mix.  The points related to cost, reliability, and quality of the products are expected to improve the chances for the growth of the manufacturers. The efforts undertaken to enhance the market dynamics such as improvement of infrastructure is expected to benefit the progress of the market in the long term. Thermo Fisher Scientific Inc., Sirchie, Merck KGaA, Copan Italia S.p.A., SARSTEDT AG & Co. KG, MWE, Luna, Puritan Medical Products, Becton, Dickinson and Company, and Medtech Forensics are some of the market players included in the report.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/forensic-swab-market-6929 

Chronic Lymphocytic Leukemia Treatment 2020 Global Market Key Players, Analysis and Forecast to 2023

 Market Scenario

As per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017. Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).

Market Drivers and Key Challenges

Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6900 

Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.

Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.

Market Segmentation

The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.

The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.

The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.

The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.

Prominent Players

The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.

Regional Insight

The chronic lymphocytic leukemia treatment market is set to expand in the region of Europe, Asia Pacific, America, and the Middle East & Africa during the assessment period.

Following a meticulous analysis of the global trends, the Americas has been identified as the leading region in the chronic lymphocytic leukemia treatment market. The increasing prevalence of leukemia, as well as the presence of prominent vendors within the region, are the main factors responsible for the strong performance of the market. In 2018, a report published by the Leukemia & Lymphoma Society stated that every 3 minutes, an individual in the United States (US) gets diagnosed with blood cancer or leukemia.

Europe has managed to seize the second largest share of the global chronic lymphocytic leukemia treatment market. Sound healthcare infrastructure, massive healthcare spending, high awareness levels with regard to relapse of Chronic Lymphocytic Leukemia (CLL) as well as related treatments, availability of reimbursement policies, use of advanced healthcare tools and the growing adoption rate of latest techniques in practice are few lucrative factors steering the CLL treatment market towards greater heights.

With the hike in the research and development activities and the presence of profitable small markets like India, Japan, China, Australia, Republic of Korea, the Asia Pacific market is expected to expand further in the subsequent years. The region is also predicted to grow at the fastest rate, backed by factors like the growing prevalence of leukemia combined with the consequently surging demand for treatment of CLL in the region. The 2017 report furnished by the World Health Organization (WHO) suggests that at least 8,904 leukemia deaths have been reported in Japan that year, indicating the rising number of cases within the region.

The most abysmal performance has been showcased by the Middle East & Africa, having managed to acquire the least share of the worldwide market. However, the lukewarm growth of the market points towards better prospects in the future, owing to the expanding healthcare infrastructure.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900